In July 2020, the U.S. government ordered 100 million doses of Pfizer/BioNTech’s experimental BNT162b2 (now known as Comirnaty) messenger RNA (mRNA) COVID-19 biologic for $1.95 billion, or $19.50 per dose. A few months later in December, it followed up with a second order for another 100 million doses of the shot for the same price.1 […]
There have been a number of reports published in the medical literature describing cases of thyroid autoimmunity developing in individuals, who have received different types of COVID-19 shots.1 Cases occur in individuals who have never been diagnosed with a thyroid disorder and in those whose thyroid disorders worsen after COVID vaccinations. The thyroid is an […]
A new study published in the journal Vaccine revealed there was a much higher risk of serious adverse events of special interest for randomized clinical trial participants who received a messenger RNA (mRNA) COVID-19 biologic when compared to participants, who received a placebo for both the Pfizer/BioNTech mRNA BNT162b2 (also known as “Comirnaty”) COVID shot […]
Concerns about the adverse effects of mRNA COVID-19 shots continue to grow a year and a half after they began to be distributed under an Emergency Use Authorization (EUA) granted to Pfizer/BioNTech and Moderna by the U.S. Food and Drug Administration (FDA). Cases of herpes zoster (HZ) following messenger RNA (mRNA) COVID shots have been […]
Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]
In a new study published in the journal Andrology, researchers found what they believe to be a temporary decline of sperm concentration and total motile count among sperm donors in Israel three months following vaccination with Pfizer/BioNTech’s BNT162b2 (also known as “Comirnaty”) messenger RNA (mRNA) COVID-19 biologic.1 Study Investigates the Effect of the Pfizer COVID […]
Since The Vaccine Reaction began publishing articles last year (Vaccinated Americans Count Their Blessings Despite Getting COVID and The Vaxxed and Boosted Get COVID But Praise Vaccines for “Mild” Symptoms) tracking members of the U.S. Congress who tested positive for SARS-CoV-2, despite being fully vaccinated and boosted, dozens of additional U.S. Senators and Representatives have tested […]
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted on June 6, […]
A study by the University College London showed that serious Guillain-Barré syndrome (GBS), which can result in temporary or permanent paralysis, is a “small but significant” risk associated with AstraZeneca/Oxford University’s AZD1222 (or “Vaxzevria”) vaccine. Of the 996 cases of GBS that were recorded in the United Kingdoms’ National Immunisation Management System database between January […]
On June 1, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) to distribute their messenger RNA (mRNA) BNT162b2 (also known as “Comirnaty”) COVID-19 biologic for children as young as six months to five years old. The application is for a three-dose regimen, […]